Trials / Recruiting
RecruitingNCT07243379
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 495 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.
Conditions
- Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia
- Multicenter Observational Study
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nanocrystalline Megestrol Acetate | Nanocrystalline Megestrol Acetate oral suspension, with a specification of 125 mg/mL, administered orally at a dose of 5 mL per day (625 mg/day), and the primary endpoint efficacy collection will be conducted in the 4th week. |
Timeline
- Start date
- 2025-09-25
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
- First posted
- 2025-11-21
- Last updated
- 2025-11-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07243379. Inclusion in this directory is not an endorsement.